The NeurologyLive® Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.
Carbidopa Levodopa Enteral Suspension Leads to Greater Cost-Effectiveness Over Standard Care
November 13th 2023Carbidopa levodopa enteral suspension for Parkinson disease demonstrated cost-effectiveness compared to standard care, with an incremental cost-effectiveness ratio of $7711/QALY in a real-world study.
Extracellular Vesicles Prove Potential Value as α-Synuclein Biomarker in Parkinson Disease
October 24th 2023The data suggest that central nervous system-derived extracellular vesicles in the blood will likely play a key role in biomarker development, especially for patients with Parkinson disease, in the coming years.
Incorporating Augmented Reality to Treat Parkinson Disease Gait Problems
October 15th 2023Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided comment on a recently published randomized controlled trial assessing the therapeutic potential of an augmented reality program for postural instability and gait dysfunction in Parkinson disease.
Improving Care Access and Utilization for Parkinson Disease: James Beck, PhD
October 11th 2023The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed a recently published Medicare claims analysis that highlighted significant issues with access to proper care for patients with Parkinson disease. [WATCH TIME: 4 minutes]
Adjusting Motor Fluctuation Management in an Era of Neuromodulation: Laxman Bahroo, DO
September 28th 2023The professor of neurology and resident program director at MedStar Georgetown University Hospital discussed how Parkinson disease motor fluctuations are managed amid new, novel technologies incorporated in the field. [WATCH TIME: 4 minutes]
Standard and Nonstandard Physical Therapy Show Similar Effectiveness for Parkinson Disease
September 26th 2023Although research supports the use of physical therapy as an effective treatment for Parkinson disease, implementation factors including type, timing, frequency, and durability of outcomes remain mainly untouched.
Role of Gut Microbiome, Alpha Synuclein in the Prodromal Stage of Parkinson Disease
September 25th 2023Virginia Gao, MD, PhD, a movement disorders fellow at Weill Cornell Medicine, discussed several topics related to the use of biomarkers in the prodromal stages of neurodegenerative disorders like Parkinson disease.
FDA Approves Image Guided Programming Software for Vercise Deep Brain Stimulation Systems
July 12th 2023The fourth-generation deep brain stimulation system is designed to treat the symptoms of Parkinson disease and essential tremor by delivering targeted electrical stimulation via surgically-implanted leads in the brain connected to an implantable pulse generators.
The Changing Landscape of Parkinson Disease and New Therapies on the Horizon: Mazen Elkurd, DO
July 3rd 2023The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the evolution of treatment for Parkinson disease and the new promising therapies patients may seen over the coming years. [WATCH TIME: 3 minutes]
Contraindicated Medication Use Significantly Impacts Length of Hospitalization in Parkinson Disease
June 14th 2023Patients with Parkinson disease who were inpatients had significant impacts on their length of stay, readmissions, and morbidity after hospitalization when administered contraindicated medications.
Filling a Therapeutic Need in Parkinson Disease: Flexibility With IPX203
June 13th 2023Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida, provided insight on the therapeutic potential of IPX203, and why it adds flexibility to the treatment of Parkinson disease.
Extended-Release Amantadine Offers More Predictable Good ON Time for Those With Parkinson Disease
June 12th 2023Pooled results of a post hoc analysis from phase 3 studies of amantadine (Gocovri; Supernus) suggest that the therapy offers increased good ON time, and in intervals that are more predictable for patients, compared with placebo.
Samelisant Shows Potential as a Treatment for Excessive Daytime Sleepiness in Parkinson Disease
June 7th 2023Preclinical findings show the potential of samelisant, a potent and orally active Histamine H3 receptor inverse agonist, as a potential treatment for patients with Parkinson disease who experience excessive daytime sleepiness.
Significant Impact of Carbidopa Levodopa Agent ND0162 in Parkinson Disease
May 24th 2023The director of the James J. and Joan A. Gardner Family Center discussed data from the phase 3 BouNDlesstrial assessing a continuous, subcutaneous levodopa/carbidopa delivery system for patients with Parkinson disease experiencing motor fluctuations. [WATCH TIME: 3 minutes]
Taking a Symptom-Based Approach to Parkinson Disease Psychosis: Aaron Ritter, MD
May 23rd 2023The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute discussed the future of treating Parkinson disease psychosis, and potential ways to lower risk of poor long-term outcomes. [WATCH TIME: 3 minutes]
Understanding the NLRP3 PET Tracer and Its Potential Impact on Parkinson Disease Treatment
May 16th 2023Marcelo Bigal, MD, PhD, chief executive officer of Ventus Therapeutics, talked about the relationship between inflammation and neurodegeneration in Parkinson disease, and the importance of targeting NLRP3.
Details Behind Potential Phase 2 Trial With UB-312 Alpha Synuclein Vaccine for Parkinson Disease
May 13th 2023Jean-Cosme Dodart, PhD, senior vice president of research at Vaxxinity, discussed the progress of the UB-312 Parkinson disease vaccine, highlighting its findings from a phase 1 clinical trial, and plans for a phase 2 trial.
Syn-One Test Reports High Sensitivity and Specificity Across Multiple Synucleinopathies
April 26th 2023CND Life Sciences’ α-synuclein skin biopsy test showed sensitivity rates ranging from 92.7% to 100% across a number of assessed and clinically confirmed synucleinopathies, including Parkinson disease and dementia with Lewy bodies, among others.
Promising Disease-Modifying Therapies in Parkinson Disease
Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
NeuroVoices: Aaron Ritter, MD, on Navigating Treatment Options for Parkinson Disease Psychosis
April 19th 2023The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided detail on an educational course that examined medication management for Parkinson disease psychosis.
Striking Differences in the Treatment of Parkinson Disease in the Last Decade
April 1st 2023In honor of Parkinson Disease Awareness Month, Hubert Fernandez, MD, director of the Center for Neurological Restoration at Cleveland Clinic, provided perspective on the advances in the care for the neurodegenerative disorder.
Blarcamesine Deemed Safe, Effective in Phase 2 Extension Study of Parkinson Disease Dementia
March 30th 2023Despite a pause in the trial due to the COVID-19 pandemic, patients who opted to continue treatment into the open-label extension demonstrated significant improvements in Parkinson disease dementia symptoms for up to 48 weeks.
SYMBYX Neuro Light Therapy Wellness Helmet Positively Impacts Parkinson Disease Symptoms
March 25th 2023Over a 12-week treatment period, patients with Parkinson disease on light therapy demonstrated statistically significant improvements of 58% and 40% in lower and upper limb coordination and movement.
Reassessing Treatment Options, Quetiapine for Parkinson Disease Psychosis: Dilesh Doshi, PharmD
March 24th 2023The vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals provided perspective on the negative effects seen from quetiapine and how the knowledge of pimavanserin has improved since approval. [WATCH TIME: 5 minutes]
Cognitive and Functional Differences Identified in Parkinson Disease Prior to Diagnosis
March 13th 2023Findings showed that global cognition declines in the prediagnostic period in men but not women with incident Parkinson disease, further indicating cognitive heterogeneity in the prodromal period by sex.
The Future of Genetic Approaches, New Targets in Parkinson Disease: James Beck, PhD
March 9th 2023The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed the potential for new therapies that target genetically mutated forms of Parkinson disease. [WATCH TIME: 3 minutes]
Reasons for the Increase in Parkinson Disease Incidence: James Beck, PhD
March 6th 2023The senior vice president and chief scientific officer of the Parkinson’s Foundation detailed some of the potential reasons for the nearly 50% increase from the previously estimated rate. [WATCH TIME: 5 minutes]
Sex, Geographic Differences in the Incidence of Parkinson Disease: James Beck, PhD
February 21st 2023The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on recently published findings showing a nearly doubling of Parkinson disease incidence that previously reported. [WATCH TIME: 4 minutes]
Greater Burden of Care Identified in Caregivers of Patients With Advanced Parkinson Disease
February 11th 2023Caregivers of patients with advancing PD were more likely to spend more hours caring per day and had a higher self-perceived burden, compared with caregivers for patients with early PD.
Inspiring and Educating Young Medical Professionals to Parkinson Disease Care: Eli Pollard
February 10th 2023The chief training and education officer at the Parkinson’s Foundation discussed the inclusion of various medical professionals that assist in Parkinson disease care, and the need to provide access to educational tools to inform clinicians. [WATCH TIME: 5 minutes]
Cognitive Impairments in Activities of Daily Living Predict Conversion to Parkinson Disease Dementia
January 26th 2023After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.
Mesdopetam Fails to Improve ON Time But Shows Anti-Dyskinesia Effects in Parkinson Disease
January 25th 2023Mesdopetam showed significant effects on the secondary end point of Unified Dyskinesia Rating Scale, an assessment of involuntary movements associated with long-term treatment with dopaminergic medication.
Research Identifies Protective Drugs Toward Parkinson Disease, Warranting Future Consideration
January 16th 2023Plain sulfonamide diuretics was identified as a drug chemical subgroup potentially inversely associated with Parkinson disease risk, while weaker signals included insulin and ß2-adrenergic agonists.
Pimavanserin Lowers Mortality Better in Parkinson Disease Than Other Atypical Antipsychotics
January 6th 2023Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.
Range of Risk Factors, Comorbidities, and Prodromal Features Identified Prior to Parkinson Disease
December 9th 2022Subsequent diagnosis of Parkinson disease was associated with a range of risk factors such as alcohol misuse and traumatic head injury, along with several other comorbidities and prodromal features.